News

Osborne Clarke advises Amphista Therapeutics on its $53M Series B funding round


Written on 18 March 2021

International legal practice Osborne Clarke has advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round.

The round was co-led by Forbion and Gilde Healthcare, with additional investors Novartis Venture Fund, and Eli Lilly and Company joining existing investor BioMotiv and founding investor Advent Life Sciences. The investment proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.

The Osborne Clarke team was led by Partner Justin Starling, with Associate Director Elizabeth Yell and Paralegal Fern Tawera in the Corporate team, and Associate Director Chris Pratt from the IP team.

Justin said: “Having acted for Amphista prior to and through its Series A it was a real pleasure to advise on this Series B round by an outstanding life sciences investor syndicate, showing the strength of Amphista’s team and their work towards delivering ground-breaking new medicines.”

Osborne Clarke has a market-leading international venture capital practice and is widely recognized as a leading European law firm for companies operating in the life science and healthcare sector. The Venture Capital team is ranked tier one by The Legal 500 and has experts across London, the Thames Valley and Bristol. It has an outstanding track record advising start-ups, global market leaders, angel investors and institutional VC/growth capital investors on funding rounds, follow-on rounds, venture debt facilities, IPOs, trade sales and buy & build projects.

Amphista Therapeutics is a biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins. The company’s pipeline of novel targeted protein degradation (TPD) based medicines is focused on challenging diseases including cancer. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised approximately £45M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly and Company.

For more information, please visit: http://www.amphista.com/